VWF and non-Hodgkin lymphoma: Brudno and Kochenderfer14 performed a review of factors contributing to CRS and NTX and found that higher peak in vivo proliferation of CAR T cells, higher cell doses, conditioning chemotherapy containing fludarabine, acute lymphocytic leukemia (ALL) rather than non-Hodgkin’s lymphoma (NHL), higher burden of disease, baseline thrombocytopenia, and baseline elevated markers of endothelial activation (e.g., angiopoietin-2 and von Willebrand factor) were all risk factors for both CRS and NTX.